Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study (Q33383828)

26 July 2017

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study (English)

1 reference

26 July 2017

phase II clinical trial

0 references

1 reference

1

Evanthia Galanis

1 reference

26 July 2017

Bernd Walter Scheithauer

12

object named as

Bernd Scheithauer

1 reference

26 July 2017

Kurt A Jaeckle

2

1 reference

26 July 2017

Matthew J Maurer

3

1 reference

26 July 2017

Joel M Reid

4

1 reference

26 July 2017

Matthew M Ames

5

1 reference

26 July 2017

James S Hardwick

6

1 reference

26 July 2017

John F Reilly

7

1 reference

26 July 2017

Andrey Loboda

8

1 reference

26 July 2017

Michael Nebozhyn

9

1 reference

26 July 2017

Valeria R Fantin

10

1 reference

26 July 2017

Victoria M Richon

11

1 reference

26 July 2017

Caterina Giannini

13

1 reference

26 July 2017

Patrick J Flynn

14

1 reference

26 July 2017

Dennis F Moore

15

1 reference

26 July 2017

James Zwiebel

16

1 reference

26 July 2017

Jan C Buckner

17

1 reference

26 July 2017

language of work or name

English

0 references

publication date

23 March 2009

1 reference

Journal of Clinical Oncology

26 July 2017

1 reference

26 July 2017

27

1 reference

26 July 2017

12

1 reference

26 July 2017

2052-2058

1 reference

Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model

26 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2669764

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2669764

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2669764

Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2669764

Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2669764

Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2669764

Modulation of radiation response by histone deacetylase inhibition

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2669764

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2669764

Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2669764

Histone Deacetylase Inhibitors: From Chromatin Remodeling to Experimental Cancer Therapeutics

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2669764

Worms gang up on bacteria

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2669764

Histone deacetylases and cancer: causes and therapies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2669764

Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2669764

Alteration of nucleosome structure as a mechanism of transcriptional regulation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2669764

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2669764

Response criteria for phase II studies of supratentorial malignant glioma

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2669764

One-sample multiple testing procedure for phase II clinical trials

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19307505

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Drug target validation and identification of secondary drug target effects using DNA microarrays

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19307505

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The fundamental role of epigenetic events in cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19307505

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2008.19.0694

1 reference

26 July 2017

1 reference

26 July 2017

1 reference